MRGPRX2 antagonism is the only known mechanism of action designed to modulate mast cells and sensory neurons, both key drivers of lesions and itch in AD.
Discover the latest advancements in atopic dermatitis treatment, including new topical agents and biologics, enhancing care for patients with moderate to severe conditions.
AbbVie reports that upadacitinib met primary and secondary endpoints, with up to 55% of patients achieving at least 80% scalp hair coverage at 24 weeks.
The statistically significant improvements seen in key HS symptoms during GLP-1 treatment for obesity suggest overlap in both mechanistic and immunologic effects.